140 related articles for article (PubMed ID: 34636462)
1. Impact of an oral gonadotropin-releasing hormone antagonist on severe ovarian hyperstimulation syndrome in a patient with breast cancer who received a sustained-release gonadotropin-releasing hormone agonist: A case report.
Hanada T; Kimura F; Kitazawa J; Morimune A; Murakami T
J Obstet Gynaecol Res; 2021 Dec; 47(12):4472-4477. PubMed ID: 34636462
[TBL] [Abstract][Full Text] [Related]
2. Severe ovarian hyperstimulation syndrome associated with long-acting GnRH agonist in oncofertility patients.
Christ J; Herndon CN; Yu B
J Assist Reprod Genet; 2021 Mar; 38(3):751-756. PubMed ID: 33471229
[TBL] [Abstract][Full Text] [Related]
3. The prevention of ovarian hyperstimulation syndrome.
Corbett S; Shmorgun D; Claman P; ;
J Obstet Gynaecol Can; 2014 Nov; 36(11):1024-1033. PubMed ID: 25574681
[TBL] [Abstract][Full Text] [Related]
4. Low dose human chorionic gonadotropin administration at the time of gonadotropin releasing-hormone agonist trigger versus 35 h later in women at high risk of developing ovarian hyperstimulation syndrome - a prospective randomized double-blind clinical trial.
Engmann LL; Maslow BS; Kaye LA; Griffin DW; DiLuigi AJ; Schmidt DW; Grow DR; Nulsen JC; Benadiva CA
J Ovarian Res; 2019 Jan; 12(1):8. PubMed ID: 30684970
[TBL] [Abstract][Full Text] [Related]
5. Which is the optimal timing for starting chemoprotection with gonadotropin-releasing hormone agonists after oocyte cryopreservation? Reflections on a critical case of ovarian hyperstimulation syndrome.
Marin L; Vitagliano A; Capobianco G; Dessole F; Ambrosini G; Andrisani A
J Gynecol Obstet Hum Reprod; 2021 Apr; 50(4):101815. PubMed ID: 32562778
[TBL] [Abstract][Full Text] [Related]
6. Triggering with human chorionic gonadotropin or a gonadotropin-releasing hormone agonist in gonadotropin-releasing hormone antagonist-treated oocyte donor cycles: findings of a large retrospective cohort study.
Bodri D; Guillén JJ; Galindo A; Mataró D; Pujol A; Coll O
Fertil Steril; 2009 Feb; 91(2):365-71. PubMed ID: 18367175
[TBL] [Abstract][Full Text] [Related]
7. Gonadotropin-releasing hormone antagonist versus agonist administration in women undergoing controlled ovarian hyperstimulation: cycle performance and in vitro steroidogenesis of granulosa-lutein cells.
Minaretzis D; Alper MM; Oskowitz SP; Lobel SM; Mortola JF; Pavlou SN
Am J Obstet Gynecol; 1995 May; 172(5):1518-25. PubMed ID: 7755066
[TBL] [Abstract][Full Text] [Related]
8. [Letrozole versus gonadotropin-releasing hormone antagonist during luteal phase in the prevention of ovarian hyperstimulation syndrome: a randomized controlled trial].
Cheng ZX; Kong G; Zhang CL; Zhao YN
Zhonghua Fu Chan Ke Za Zhi; 2020 Jan; 55(1):9-14. PubMed ID: 32074767
[No Abstract] [Full Text] [Related]
9. Tamoxifen co-administration during controlled ovarian hyperstimulation for in vitro fertilization in breast cancer patients increases the safety of fertility-preservation treatment strategies.
Meirow D; Raanani H; Maman E; Paluch-Shimon S; Shapira M; Cohen Y; Kuchuk I; Hourvitz A; Levron J; Mozer-Mendel M; Brengauz M; Biderman H; Manela D; Catane R; Dor J; Orvieto R; Kaufman B
Fertil Steril; 2014 Aug; 102(2):488-495.e3. PubMed ID: 24934489
[TBL] [Abstract][Full Text] [Related]
10. The use of gonadotropin-releasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high-risk patients undergoing in vitro fertilization prevents the risk of ovarian hyperstimulation syndrome: a prospective randomized controlled study.
Engmann L; DiLuigi A; Schmidt D; Nulsen J; Maier D; Benadiva C
Fertil Steril; 2008 Jan; 89(1):84-91. PubMed ID: 17462639
[TBL] [Abstract][Full Text] [Related]
11. Ovarian hyperstimulation syndrome prevention by gonadotropin-releasing hormone agonist triggering of final oocyte maturation in a gonadotropin-releasing hormone antagonist protocol in combination with a "freeze-all" strategy: a prospective multicentric study.
Griesinger G; Schultz L; Bauer T; Broessner A; Frambach T; Kissler S
Fertil Steril; 2011 May; 95(6):2029-33, 2033.e1. PubMed ID: 21371705
[TBL] [Abstract][Full Text] [Related]
12. Gonadotropin-releasing hormone agonist ovulation trigger-beyond OHSS prevention.
Castillo JC; Haahr T; Martínez-Moya M; Humaidan P
Ups J Med Sci; 2020 May; 125(2):138-143. PubMed ID: 32208810
[TBL] [Abstract][Full Text] [Related]
13. Triggering ovulation with gonadotropin-releasing hormone agonist in in vitro fertilization patients with polycystic ovaries does not cause ovarian hyperstimulation syndrome despite very high estradiol levels.
Manzanares MA; Gómez-Palomares JL; Ricciarelli E; Hernández ER
Fertil Steril; 2010 Mar; 93(4):1215-9. PubMed ID: 19200978
[TBL] [Abstract][Full Text] [Related]
14. Severe ovarian hyperstimulation syndrome after combined GnRH-agonist and low-dose human chorionic gonadotropin trigger in a patient with a single kidney.
Pereira N; Lekovich JP; Kligman I; Rosenwaks Z
Gynecol Endocrinol; 2017 Aug; 33(8):593-597. PubMed ID: 28440686
[TBL] [Abstract][Full Text] [Related]
15. Ovarian hyperstimulation following the sole administration of agonistic analogues of gonadotrophin releasing hormone.
Weissman A; Barash A; Shapiro H; Casper RF
Hum Reprod; 1998 Dec; 13(12):3421-4. PubMed ID: 9886527
[TBL] [Abstract][Full Text] [Related]
16. Ovarian hyper-response to administration of an GnRH-agonist without gonadotropins.
Park HT; Bae HS; Kim T; Kim SH
J Korean Med Sci; 2011 Oct; 26(10):1394-6. PubMed ID: 22022197
[TBL] [Abstract][Full Text] [Related]
17. Triggering final oocyte maturation with gonadotropin-releasing hormone agonist (GnRHa) versus human chorionic gonadotropin (hCG) in breast cancer patients undergoing fertility preservation: an extended experience.
Reddy J; Turan V; Bedoschi G; Moy F; Oktay K
J Assist Reprod Genet; 2014 Jul; 31(7):927-32. PubMed ID: 24854484
[TBL] [Abstract][Full Text] [Related]
18. Basic understanding of gonadotropin-releasing hormone-agonist triggering.
Casper RF
Fertil Steril; 2015 Apr; 103(4):867-9. PubMed ID: 25712575
[TBL] [Abstract][Full Text] [Related]
19. Gonadotropin-Releasing Hormone-Agonist Triggering and a Freeze-All Approach: The Final Step in Eliminating Ovarian Hyperstimulation Syndrome?
Davenport MJ; Vollenhoven B; Talmor AJ
Obstet Gynecol Surv; 2017 May; 72(5):296-308. PubMed ID: 28558117
[TBL] [Abstract][Full Text] [Related]
20. Short coasting of 1 or 2 days by withholding both gonadotropins and gonadotropin-releasing hormone agonist prevents ovarian hyperstimulation syndrome without compromising the outcome.
Moon HS; Joo BS; Moon SE; Lee SK; Kim KS; Koo JS
Fertil Steril; 2008 Dec; 90(6):2172-8. PubMed ID: 18439601
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]